Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases
Clinical trial NCT05012787 · TERMINATED
Trial details
- NCT number
- NCT05012787
- Sponsor
- Clover Biopharmaceuticals AUS Pty
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-12
- Primary completion
- 2022-03-30
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.